Journal
PHARMACOGENOMICS
Volume 8, Issue 9, Pages 1151-1158Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/14622416.8.9.1151
Keywords
ABCB1; drug; response; intractable epilepsy; multidrug resistance; pharmacogenetics; PXR
Categories
Ask authors/readers for more resources
Objectives: The aim of this study was to investigate whether the polymorphisms in the NR112 and ABCB1 genes were associated with epilepsy treatment responses. Methods & results: NR112 and ABCB1 polymorphisms were genotyped in 114 drug-resistant epileptic patients, 213 seizure-free patients and 287 normal controls. Highly specific real-time PCR was applied to detect the variants by using TaqMan allelic specific probe. For a single gene test, it was demonstrated that 3435C>T in the ABCB1 gene had a significant effect on epilepsy treatment responses, but polymorphisms in the NR112 gene did not. Further analysis using a logistic regression model revealed that only 2677G>T and 3435C>T in the ABCB1 gene and their interaction term were associated with drug-resistant epilepsy after adjustment for etiology and epilepsy classification. In the present study, the polymorphisms in the NR112 gene were not significantly associated with epilepsy treatment responses. Conclusion: Our results indicated that 2677G>T and 3435C > T in the ABCB1 gene contributed to drug-resistant epilepsy. Although biologically plausible, the polymorphisms in NR112 investigated in the present study did not play a role in epilepsy treatment responses. Other unveiled genetic variants in the NR112 gene that may have the potential to affect ABCB1 gene expression are worth further investigation in future studies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available